vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and HARTE HANKS INC (HHS). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($71.7M vs $39.9M, roughly 1.8× HARTE HANKS INC). HARTE HANKS INC runs the higher net margin — 5.5% vs -18.9%, a 24.5% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs -15.4%). Adaptive Biotechnologies Corp produced more free cash flow last quarter ($1.4M vs $-686.0K). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs -6.4%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
ADPT vs HHS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $39.9M |
| Net Profit | $-13.6M | $2.2M |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | -0.3% |
| Net Margin | -18.9% | 5.5% |
| Revenue YoY | 51.0% | -15.4% |
| Net Profit YoY | 59.7% | — |
| EPS (diluted) | $-0.08 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $39.9M | ||
| Q3 25 | $94.0M | $39.5M | ||
| Q2 25 | $58.9M | $38.6M | ||
| Q1 25 | $52.4M | $41.6M | ||
| Q4 24 | $47.5M | $47.1M | ||
| Q3 24 | $46.4M | $47.6M | ||
| Q2 24 | $43.2M | $45.0M | ||
| Q1 24 | $41.9M | $45.4M |
| Q4 25 | $-13.6M | $2.2M | ||
| Q3 25 | $9.5M | $-2.3M | ||
| Q2 25 | $-25.6M | $-335.0K | ||
| Q1 25 | $-29.9M | $-392.0K | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | $142.0K | ||
| Q2 24 | $-46.2M | $-27.8M | ||
| Q1 24 | $-47.5M | $-171.0K |
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | -0.3% | ||
| Q3 25 | 10.9% | 1.3% | ||
| Q2 25 | -42.5% | 0.1% | ||
| Q1 25 | -56.4% | -0.1% | ||
| Q4 24 | -71.3% | -3.3% | ||
| Q3 24 | -70.3% | 4.0% | ||
| Q2 24 | -109.6% | 3.0% | ||
| Q1 24 | -116.5% | 0.8% |
| Q4 25 | -18.9% | 5.5% | ||
| Q3 25 | 10.2% | -5.8% | ||
| Q2 25 | -43.5% | -0.9% | ||
| Q1 25 | -56.9% | -0.9% | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | 0.3% | ||
| Q2 24 | -107.0% | -61.8% | ||
| Q1 24 | -113.5% | -0.4% |
| Q4 25 | $-0.08 | $0.30 | ||
| Q3 25 | $0.06 | $-0.31 | ||
| Q2 25 | $-0.17 | $-0.05 | ||
| Q1 25 | $-0.20 | $-0.05 | ||
| Q4 24 | $-0.22 | $-0.31 | ||
| Q3 24 | $-0.22 | $0.02 | ||
| Q2 24 | $-0.31 | $-3.84 | ||
| Q1 24 | $-0.33 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $5.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $20.5M |
| Total Assets | $512.7M | $91.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $5.6M | ||
| Q3 25 | $55.0M | $6.5M | ||
| Q2 25 | $43.2M | $4.8M | ||
| Q1 25 | $50.6M | $9.0M | ||
| Q4 24 | $47.9M | $9.8M | ||
| Q3 24 | $38.1M | $5.9M | ||
| Q2 24 | $59.8M | $11.0M | ||
| Q1 24 | $71.2M | $11.5M |
| Q4 25 | $218.8M | $20.5M | ||
| Q3 25 | $204.4M | $19.9M | ||
| Q2 25 | $179.7M | $22.2M | ||
| Q1 25 | $190.4M | $21.4M | ||
| Q4 24 | $202.7M | $21.7M | ||
| Q3 24 | $223.8M | $21.0M | ||
| Q2 24 | $241.6M | $20.6M | ||
| Q1 24 | $274.9M | $20.0M |
| Q4 25 | $512.7M | $91.8M | ||
| Q3 25 | $490.6M | $92.7M | ||
| Q2 25 | $496.6M | $95.0M | ||
| Q1 25 | $510.9M | $100.6M | ||
| Q4 24 | $539.4M | $101.8M | ||
| Q3 24 | $558.5M | $108.1M | ||
| Q2 24 | $584.9M | $109.7M | ||
| Q1 24 | $620.3M | $113.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $737.0K |
| Free Cash FlowOCF − Capex | $1.4M | $-686.0K |
| FCF MarginFCF / Revenue | 2.0% | -1.7% |
| Capex IntensityCapex / Revenue | 0.9% | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $-4.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $737.0K | ||
| Q3 25 | $-7.1M | $3.2M | ||
| Q2 25 | $-12.4M | $-4.8M | ||
| Q1 25 | $-28.5M | $-818.0K | ||
| Q4 24 | $-12.5M | $4.0M | ||
| Q3 24 | $-27.1M | $-2.9M | ||
| Q2 24 | $-17.3M | $1.6M | ||
| Q1 24 | $-38.4M | $-5.7M |
| Q4 25 | $1.4M | $-686.0K | ||
| Q3 25 | $-7.5M | $2.2M | ||
| Q2 25 | $-13.1M | $-5.1M | ||
| Q1 25 | $-29.7M | $-923.0K | ||
| Q4 24 | $-12.6M | $3.4M | ||
| Q3 24 | $-27.4M | $-4.9M | ||
| Q2 24 | $-19.0M | $926.0K | ||
| Q1 24 | $-39.9M | $-6.2M |
| Q4 25 | 2.0% | -1.7% | ||
| Q3 25 | -8.0% | 5.5% | ||
| Q2 25 | -22.2% | -13.1% | ||
| Q1 25 | -56.7% | -2.2% | ||
| Q4 24 | -26.5% | 7.3% | ||
| Q3 24 | -59.0% | -10.2% | ||
| Q2 24 | -44.1% | 2.1% | ||
| Q1 24 | -95.2% | -13.7% |
| Q4 25 | 0.9% | 3.6% | ||
| Q3 25 | 0.4% | 2.5% | ||
| Q2 25 | 1.1% | 0.6% | ||
| Q1 25 | 2.4% | 0.3% | ||
| Q4 24 | 0.2% | 1.3% | ||
| Q3 24 | 0.7% | 4.0% | ||
| Q2 24 | 4.0% | 1.5% | ||
| Q1 24 | 3.6% | 1.2% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -20.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
